Department of Psychiatry, Psychotherapy, and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel, Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg-Essen, Germany.
Medical Study Center of the Evangelische. Krankenhausgemeinschaft Herne | Castrop-Rauxel gGmbH, Herne, Germany.
Fortschr Neurol Psychiatr. 2023 Jul;91(7-08):297-310. doi: 10.1055/a-1826-2888. Epub 2022 Jul 26.
Internet-based self-help-programs like deprexis have been increasingly shown to reduce depressive symptoms if added to distinct, primarily outpatient-treatment-settings. There is limited information about the effectiveness of deprexis if started at routine psychiatric hospital inpatient treatment of moderate-to-severe major depressive disorder (MDD).
To examine, sixty-nine adult MDD-inpatients were randomly assigned to a 12-week-period of treatment-as-usual (TAU, N=33) or TAU plus guided deprexis (TAU-PLUS, N=36). The study was planned as a pragmatic approach considering psychiatric routine conditions, particularly, offering an instant and flexible discharge management when the patients felt stabilized enough for primary/secondary care. Therefore, there was no fixed time frame for the inpatient treatment duration. Post-discharge, patients were followed by structured telephone interviews up to study-endpoint, i. e., 12 weeks after deprexis-initiation. Primary (Beck-Depression-Inventory-II, BDI-II) and secondary outcome-measures (Hamilton-Depression-Scale, Clinical-Global-Impression-Severity, WHO-Well-Being-Index, Helping-Alliance-Questionnaire) were carried out at study entry and every 2 weeks. Furthermore, the working alliance with deprexis as well as the inpatient treatment duration, the daily activity and the utilization of post-hospital care after discharge were determined.
At week 12, modified ITT-analyses showed significant between-group differences of BDI-II scores in favor of the TAU-PLUS-patients (p=.03) corresponding to a medium effect size (d=-.73, 95% CI -1.4 to .06). TAU-PLUS-patients showed greater daily activity (p=.04, d=.70, 95% CI -.03 to 1.38) and had been discharged significantly earlier from inpatient treatment (p=.003). Post-discharge, the TAU-PLUS-group reported a lower rate of post-hospital care (p=.01) and re-admissions (p=.04). Secondary outcome-measures including the alliance with the therapists were not significantly different between the groups at study-endpoint. The patients´ working-alliance with deprexis significantly predicted MDD-improvement and wellbeing. Both groups (TAU and TAU plus deprexis) were comparable with regard to the prescribed antidepressant medication. Unfortunately, detailed data on the amount and actual duration of the psychotherapeutic and special therapeutic individual and group settings of the TAU were not collected CONCLUSION: TAU plus deprexis was superior to TAU in improving subjective depression-severity (BDI-II) and daily activity in patients having sought psychiatric inpatient MDD-treatment before. This beneficial effect appeared 12 weeks after inpatient deprexis-initiation, i. e. when the vast majority of patients were back in primary/secondary care. Adjunctive deprexis was associated with earlier discharges and a significant advantage for post-hospital stabilization. In this regard, it could be promising to include deprexis into inpatient treatment conditions, thereby also preparing its continuing outpatient use. We found no evidence that deprexis interfered negatively with the alliance between the patients and their therapists.
如果将基于互联网的自助计划(如 deprexis)与明确的主要门诊治疗环境相结合,可以减少抑郁症状。关于在常规精神科医院住院治疗中度至重度重度抑郁症(MDD)时开始使用 deprexis 的效果,信息有限。
为了研究,69 名成年 MDD 住院患者被随机分配到为期 12 周的常规治疗(TAU,N=33)或 TAU 加指导 deprexis(TAU-PLUS,N=36)。该研究计划采用实用方法考虑精神科常规条件,特别是在患者感到足够稳定以接受初级/二级护理时提供即时灵活的出院管理。因此,没有固定的住院治疗时间框架。出院后,通过结构化电话访谈对患者进行随访,直至研究终点,即 deprexis 开始后 12 周。主要(贝克抑郁量表第二版,BDI-II)和次要结局测量(汉密尔顿抑郁量表、临床总体印象严重程度、世界卫生组织幸福指数、帮助联盟问卷)在研究开始时和每 2 周进行一次。此外,还确定了与 deprexis 的工作联盟以及住院治疗时间、日常活动和出院后的后续护理使用情况。
在第 12 周,意向治疗分析显示,TAU-PLUS 患者的 BDI-II 评分有显著的组间差异,有利于 TAU-PLUS 患者(p=.03),对应中等效应大小(d=-.73,95% CI -1.4 至.06)。TAU-PLUS 患者的日常活动(p=.04,d=.70,95% CI -.03 至 1.38)更大,并且更早地从住院治疗中出院(p=.003)。出院后,TAU-PLUS 组报告的后续护理(p=.01)和再入院(p=.04)率较低。研究结束时,两组之间的次要结局测量(包括与治疗师的联盟)没有显著差异。患者与 deprexis 的工作联盟与 MDD 改善和幸福感显著相关。两组(TAU 和 TAU 加 deprexis)在规定的抗抑郁药物方面相当。不幸的是,关于 TAU 的心理治疗和特殊治疗个体和团体设置的数量和实际持续时间的详细数据没有收集。
在寻求精神科住院 MDD 治疗的患者中,TAU 加 deprexis 在改善主观抑郁严重程度(BDI-II)和日常活动方面优于 TAU。这种有益效果出现在住院 deprexis 开始后 12 周,即绝大多数患者返回初级/二级护理时。附加的 deprexis 与更早的出院和出院后的稳定显著相关。在这方面,将 deprexis 纳入住院治疗条件可能是有希望的,从而也为其后续门诊使用做好准备。我们没有发现 deprexis 对患者及其治疗师之间的联盟产生负面影响的证据。